Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:EMC NASDAQ:IMV NYSEAMERICAN:MTNB NYSE:MVF TSE:RVX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$31.11+1.8%$0.00$22.99▼$29.13N/AN/A13.90 million shs4,500 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsMTNBMatinas Biopharma$1.86+1.4%$1.76$0.47▼$4.25$9.47M1.43377,231 shs7,238 shsMVFBlackRock MuniVest Fund$7.05-0.1%$6.78$6.43▼$7.61$403.96M0.56109,028 shs70,602 shsRVXResverlogixC$0.10-9.1%C$0.10C$0.04▼C$0.30C$28.64M0.677504107,022 shs112,644 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC0.00%-3.16%-0.39%+5.17%+8.77%IMVIMV0.00%0.00%0.00%0.00%0.00%MTNBMatinas Biopharma+7.31%-3.52%+0.27%+85.28%+888.15%MVFBlackRock MuniVest Fund+0.44%+1.88%+2.02%+8.03%-6.02%RVXResverlogix0.00%+4.76%+22.22%+46.67%+57.14%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEMCEMC$31.11+1.8%$0.00$22.99▼$29.13N/AN/A13.90 million shs4,500 shsIMVIMV$0.66$0.48▼$12.70$9.63M0.95233,607 shs44,800 shsMTNBMatinas Biopharma$1.86+1.4%$1.76$0.47▼$4.25$9.47M1.43377,231 shs7,238 shsMVFBlackRock MuniVest Fund$7.05-0.1%$6.78$6.43▼$7.61$403.96M0.56109,028 shs70,602 shsRVXResverlogixC$0.10-9.1%C$0.10C$0.04▼C$0.30C$28.64M0.677504107,022 shs112,644 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEMCEMC0.00%-3.16%-0.39%+5.17%+8.77%IMVIMV0.00%0.00%0.00%0.00%0.00%MTNBMatinas Biopharma+7.31%-3.52%+0.27%+85.28%+888.15%MVFBlackRock MuniVest Fund+0.44%+1.88%+2.02%+8.03%-6.02%RVXResverlogix0.00%+4.76%+22.22%+46.67%+57.14%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEMCEMC 0.00N/AN/AN/AIMVIMV 0.00N/AN/AN/AMTNBMatinas Biopharma 2.00HoldN/AN/AMVFBlackRock MuniVest Fund 0.00N/AN/AN/ARVXResverlogix 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEMCEMCN/AN/AN/AN/AN/AN/AIMVIMV$330K0.00N/AN/A($0.69) per share0.00MTNBMatinas Biopharma$1.10M8.19N/AN/A$1.49 per share1.19MVFBlackRock MuniVest FundN/AN/AN/AN/AN/AN/ARVXResverlogixN/AN/AC$0.00 per share132.50C($0.23) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEMCEMCN/A$2.0515.18∞N/AN/AN/AN/AN/AIMVIMV-$37.99M-$4.59N/AN/AN/A-11,547.42%-12,695.41%-104.84%N/AMTNBMatinas Biopharma-$24.25M-$3.89N/A∞N/AN/A-210.21%-138.39%N/AMVFBlackRock MuniVest FundN/AN/A0.00∞N/AN/AN/AN/AN/ARVXResverlogix-C$2.81M-C$0.04N/A∞N/AN/A6.06%-34.90%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEMCEMC$0.461.48%N/A22.44%N/AIMVIMVN/AN/AN/AN/AN/AMTNBMatinas BiopharmaN/AN/AN/AN/AN/AMVFBlackRock MuniVest Fund$0.223.11%N/AN/AN/ARVXResverlogixN/A7.02%N/AN/AN/ALatest RVX, EMC, MTNB, IMV, and MVF DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date10/1/2025MVFBlackRock MuniVest Fundmonthly$0.03606.21%10/15/202510/15/202511/3/20259/2/2025MVFBlackRock MuniVest Fundmonthly$0.03606.23%9/15/20259/15/202510/1/20258/1/2025MVFBlackRock MuniVest Fundmonthly$0.03606.5%8/15/20258/15/20259/2/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEMCEMCN/AN/AN/AIMVIMVN/A2.932.93MTNBMatinas BiopharmaN/A4.074.07MVFBlackRock MuniVest FundN/AN/AN/ARVXResverlogix-10.950.130.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEMCEMC79.86%IMVIMV15.37%MTNBMatinas Biopharma11.77%MVFBlackRock MuniVest Fund48.16%RVXResverlogix0.01%Insider OwnershipCompanyInsider OwnershipEMCEMC0.40%IMVIMV0.33%MTNBMatinas Biopharma4.60%MVFBlackRock MuniVest Fund1.00%RVXResverlogix42.66%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEMCEMCN/AN/AN/ANot OptionableIMVIMV9711.71 million11.67 millionOptionableMTNBMatinas Biopharma305.09 million4.85 millionN/AMVFBlackRock MuniVest Fund147,00057.34 million56.76 millionNot OptionableRVXResverlogix19286.44 millionN/ANot OptionableRVX, EMC, MTNB, IMV, and MVF HeadlinesRecent News About These CompaniesResverlogix Corp.: Resverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finanznachrichten.deResverlogix Announces Voting Results from the 2025 Meeting of ShareholdersJune 30, 2025 | finance.yahoo.comNew beanless 'coffee' emerges but does it taste any good?September 17, 2024 | bbc.comBNumerous Independent Groups Presented Data that Supports Apabetalone’s Potential Cardioprotective Benefits at European Society of Cardiology Congress 2024September 3, 2024 | msn.comResverlogix: Top 10 Undervalued Biotechnology Industry Stocks (RVX)September 3, 2024 | theglobeandmail.comResverlogix Corp. (RVXCF)July 31, 2024 | finance.yahoo.comResverlogix Announces Voting Results from the 2024 Meeting of Shareholders and Closing of Debenture ExtensionJuly 31, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp up on Tuesday (RVX)July 28, 2024 | theglobeandmail.comClosing Bell: Resverlogix Corp flat on Wednesday (RVX)July 25, 2024 | theglobeandmail.comResverlogix Announces Updated Annual and Special Meeting of ShareholdersMay 28, 2024 | finance.yahoo.comResverlogix Corp. (RVX.TO)May 16, 2024 | finance.yahoo.comResverlogix Announces Two-Year Extension of Debenture and Elimination of Conversion PrivilegesMay 13, 2024 | finance.yahoo.comResverlogix Announces Change to Its Board of DirectorsFebruary 21, 2024 | finance.yahoo.comResverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic BenefitsJanuary 11, 2024 | finance.yahoo.comClosing Bell: Resverlogix Corp flat on Tuesday (RVX)January 4, 2024 | theglobeandmail.comResverlogix Corp. (RVX) Earnings Dates & ReportsDecember 19, 2023 | investing.comResverlogix Corp RVXCFNovember 18, 2023 | morningstar.comMResverlogix Corp RVXNovember 1, 2023 | morningstar.comMResverlogix: Top 10 Undervalued Healthcare Sector Stocks on TSX (RVX)October 18, 2023 | theglobeandmail.comResverlogix Corp.: Resverlogix Publishes on Apabetalone's Potential for the Treatment of FSHD, the Third Most Common Muscular DystrophyOctober 4, 2023 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRVX, EMC, MTNB, IMV, and MVF Company DescriptionsEMC NYSE:EMCEMC Corporation (EMC) develops, delivers and supports the information technology (IT) industry's range of information infrastructure and virtual infrastructure technologies, solutions and services. EMC manages the Company as part of a federation of businesses: EMC Information Infrastructure, VMware Virtual Infrastructure, Pivotal and Virtustream. EMC's Information Infrastructure business provides a foundation for organizations to store, manage, protect, analyze and secure information. EMC's VMware Virtual Infrastructure business is engaged in virtualization and cloud infrastructure solutions that enable businesses to help transform the way they build, deliver and consume IT resources in a manner that is based on their specific needs. EMC's Pivotal business unites strategic technology, people and programs from EMC and VMware and has a platform that consists of data, agile development practices and a cloud independent platform-as-a-service.IMV NASDAQ:IMVIMV, Inc. is a clinical-stage biopharmaceutical company, which engage in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. Its immune-educating technology includes DPX which is designed to inform a specific, coordinated, and persistent anti-tumor immune response. The company was founded on May 18, 2007 and is headquartered in Dartmouth, Canada.Matinas Biopharma NYSEAMERICAN:MTNB$1.86 +0.03 (+1.36%) As of 01:38 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.BlackRock MuniVest Fund NYSE:MVF$7.04 -0.01 (-0.07%) As of 01:02 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BlackRock MuniVest Fund, Inc. is a closed-ended fixed income mutual fund launched by BlackRock, Inc. It is managed by BlackRock Advisors, LLC. The fund invests in the fixed income markets of the United States. It primarily invests in investment grade, long term municipal obligations that are exempt from federal income taxes. The fund seeks to invest in securities with maturities of more than ten years. BlackRock MuniVest Fund, Inc. was formed on September 29, 1988 and is domiciled in the United States.Resverlogix TSE:RVXC$0.10 -0.01 (-9.09%) As of 01:26 PM EasternResverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA Analysts Lift Targets: What It Means for the Stock Price Fastenal Stock Pulls Back in October—Is It Time to Buy FAST? 5 Stocks and ETFs to Weather Volatility as Trade Tensions Rise Why Congress Is Buying Intuitive Surgical Ahead of Earnings D-Wave: Reevaluating the Short Seller’s Case After the Downgrade 3 Dividend Hikes That Signal Renewed Strength in 2025 2 Reasons Absci Could Be the Future of AI Biotech, and 1 Risk Applied Digital’s Shorts Got Squeezed—Now What? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
